Immunohistochemical characterization of nurse cells in normal human thymus

1991 ◽  
Vol 96 (6) ◽  
pp. 499-503 ◽  
Author(s):  
B. Dipasquale ◽  
G. Tridente
Blood ◽  
2002 ◽  
Vol 99 (12) ◽  
pp. 4400-4405 ◽  
Author(s):  
Suzanne Burns ◽  
Murat O. Arcasoy ◽  
Li Li ◽  
Elizabeth Kurian ◽  
Katri Selander ◽  
...  

A drug that specifically inhibits erythropoiesis would be clinically useful. The erythropoietin (Epo) mutant Epo (R103A) could potentially be used for this purpose. Epo (R103A) has a single amino acid substitution of alanine for arginine at position 103. Because of this mutation, Epo (R103A) is only able to bind to one of the 2 subunits of the erythropoietin receptor (EpoR) homodimer and is thus a competitive inhibitor of Epo activity. To produce large quantities of Epo (R103A) to test in animal models of thalassemia and sickle cell disease, we expressed and purified recombinant Epo (R103A) from the yeast Pichia pastoris. Using this method milligram quantities of highly purified Epo (R103A) are obtained. The yeast-expressed Epo (R103A) is properly processed and glycosylated and specifically inhibits Epo-dependent cell growth and125I-Epo binding. Epo (R103A) does not, however, directly induce apoptosis in 32D cells expressing EpoR. Epo (R103A) inhibits erythropoiesis of human CD34+ hematopoietic cells and completely blocks erythroid burst-forming unit formation in normal human bone marrow colony assays. Yeast-expressed Epo (R103A) is a specific inhibitor of primary erythropoiesis suitable for testing in animal models.


2009 ◽  
Vol 18 (10) ◽  
pp. 1417-1422 ◽  
Author(s):  
Katalin Dezső ◽  
Sándor Paku ◽  
Veronika Papp ◽  
Eszter Turányi ◽  
Peter Nagy

1986 ◽  
Vol 6 (9) ◽  
pp. 3109-3116 ◽  
Author(s):  
C Birchmeier ◽  
D Birnbaum ◽  
G Waitches ◽  
O Fasano ◽  
M Wigler

A human oncogene, mcf3, previously detected by a combination of DNA-mediated gene transfer and a tumorigenicity assay, derives from a human homology of the avian v-ros oncogene. Both v-ros and mcf3 can encode a protein with homology to tyrosine-specific protein kinases, and both mcf3 and v-ros encode a potential transmembrane domain N terminal to the kinase domain. mcf3 probably arose during gene transfer from a normal human ros gene by the loss of a putative extracellular domain. There do not appear to be any other gross rearrangements in the structure of mcf3.


1993 ◽  
Vol 151 (2) ◽  
pp. 481-490 ◽  
Author(s):  
Yukiyasu Takeuchi ◽  
Yoshitaka Fujii ◽  
Meinoshin Okumura ◽  
Keiji Inada ◽  
Kazuya Nakahara ◽  
...  
Keyword(s):  

Immunobiology ◽  
2018 ◽  
Vol 223 (1) ◽  
pp. 57-63 ◽  
Author(s):  
Jorge Gutierrez-Franco ◽  
Rodolfo Hernandez-Gutierrez ◽  
Miriam Ruth Bueno-Topete ◽  
Jesse Haramati ◽  
Rosa Elena Navarro-Hernandez ◽  
...  

1993 ◽  
Vol 54 (2) ◽  
pp. 143-153 ◽  
Author(s):  
Masaya Okura ◽  
Kanemitsu Shirasuna ◽  
Tsutomu Hiranuma ◽  
Hideo Yoshioka ◽  
Hirokazu Nakahara ◽  
...  

2003 ◽  
Vol 71 (7) ◽  
pp. 3875-3884 ◽  
Author(s):  
Christian Theilacker ◽  
Fadie T. Coleman ◽  
Simone Mueschenborn ◽  
Nicolas Llosa ◽  
Martha Grout ◽  
...  

ABSTRACT Deterioration of lung function in patients with cystic fibrosis (CF) is closely associated with chronic pulmonary infection with mucoid Pseudomonas aeruginosa. The mucoid exopolysaccharide (MEP) from P. aeruginosa has been shown to induce opsonic antibodies in mice that are protective against this chronic infection. MEP-specific opsonic antibodies are also commonly found in the sera of older CF patients lacking detectable P. aeruginosa infection. When used in a human vaccine trial, however, MEP only minimally induced opsonic antibodies. To evaluate whether conjugation of MEP to a carrier protein could improve its immunogenicity, we bound thiolated MEP to keyhole limpet hemocyanin (KLH) by using succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) as a linker. In contrast to the native MEP polymer, the MEP-KLH conjugate vaccine induced high titers of MEP-specific immunoglobulin G (IgG) in C3H-HeN mice and in a rabbit. Sera from mice immunized with MEP-KLH conjugate, but not from animals immunized with comparable doses of native MEP, demonstrated opsonic killing activity. Vaccination with MEP-KLH conjugate induced opsonic antibodies broadly cross-reactive to heterologous mucoid strains of P. aeruginosa. Preexisting nonopsonic antibodies to MEP are found in normal human sera, including young CF patients, and their presence impedes the induction of opsonic antibodies. Induction of nonopsonic antibodies by either intraperitoneal injection of MEP or injection or feeding of the cross-reactive antigen, seaweed alginate, reduced the level of overall IgG elicited by follow-up immunization with the MEP-KLH conjugate. However, the opsonic activity was lower only in the sera of MEP-KLH conjugate-immunized mice with preexisting antibodies induced by MEP but not with antibodies induced by seaweed alginate. Immunization with MEP-KLH elicited a significant proportion of antibodies specific to epitopes involving O-acetate residues, and this subpopulation of antibodies mediated opsonic killing of mucoid P. aeruginosa in vitro. These results indicate that conjugation of MEP to KLH significantly enhances its immunogenicity and the elicitation of opsonic antibodies in mice and rabbits, that the conjugate induces opsonic antibodies in the presence of preexisting nonopsonic antibodies, and that opsonic antibodies to MEP are directed at epitopes that include acetate residues on the uronic acid polymer.


2017 ◽  
Vol 293 (3) ◽  
pp. 906-919 ◽  
Author(s):  
Tao Huang ◽  
Mary Mathieu ◽  
Sophia Lee ◽  
Xinhua Wang ◽  
Yee Seir Kee ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document